Concepedia

Publication | Closed Access

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

DOI

1K

Citations

22

References

2007

Year

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa Pacheco, Francine M. Foss, Sareeta Parker, Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduino,
Journal of Clinical Oncology

Abstract

Oral vorinostat was effective in treatment refractory MF/SS with an acceptable safety profile.

References

YearCitations

Page 1